Pipeline

Drug development landscape · phase attrition · therapeutic area trends

Phase 1

47K

First-in-human dose finding

Phase 2

64K

Efficacy & safety signal

Phase 3

41K

Pivotal confirmatory trials

Phase 4

35K

Post-approval surveillance

Phase Pipeline Landscape

Trial counts by phase · avg. participants per trial on the right

Early Ph. 16K

avg 95 pts

764% next-phase ratio

Phase 147K

avg 51 pts

135% next-phase ratio

Phase 264K

avg 138 pts

65% next-phase ratio

Phase 341K

avg 688 pts

85% next-phase ratio

Phase 435K

avg 693 pts

Therapeutic Area Trends

New trial starts per year by condition (2010 – present)

Annual Trial Activity

New trials started (bars, left axis) and total enrollment (line, right axis)

Average Enrollment by Phase

Trials with enrollment data

Phase	Avg Participants	Total Enrolled	Trial Count
Early Ph. 1	95	558K	6K
Phase 1	51	2.3M	45K
Phase 2	138	8.3M	60K
Phase 3	688	27.2M	39K
Phase 4	693	23.1M	33K